- Shares of Trovagene (TROV +16.6%) soar as the company announces the availability of the first urine test for cancer mutation monitoring.
- The cell-free BRAF test detects and monitors V600E BRAF mutation, replacing tissue sample-based monitoring which "has limited practicality for patient monitoring due to costs, tumor heterogeneity and potential complications from the biopsy process." (PR)
- Aegis' Raghuram Selvaraju says the news marks "a significant milestone for the company and [is] a core component of the firm's strategy aimed at attaining profitability near-term."
Trovagene leaps on urine-based cancer mutation test news
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs